NCT00266253View on ClinicalTrials.gov

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

GK Activator (2)

Escalating doses, po bid or qd for 12 weeks.

DRUG

Metformin

As prescribed, for 12 weeks

Trial Locations (47)

2050

Sydney

3081

Heidelberg

5000

Adelaide

10115

Berlin

19067

Morrisville

19107

Philadelphia

20249

Hamburg

30045

Lawrenceville

33603

Tampa

34741

Kissimmee

35385

Giessen

36142

Tann

38119

Memphis

45355

Essen

45429

Kettering

46600

Alzira

48903

Barakaldo

49616

Benzonia

59701

Butte

65804

Springfield

67005

Arkansas City

68161

Mannheim

69245

Bammental

74104

Tulsa

85012

Phoenix

90057

Los Angeles

90402

Nuremberg

91910

Chula Vista

94550

Künzing

97504

Medford

98003

Federal Way

98004

Bellevue

T5N 3Y6

Edmonton

V5Z 1M9

Vancouver

NGA 4V2

London

H1T 2M4

Montreal

J1H 4J6

Sherbrooke

02826

Görlitz

03114

Bacarot Alicant

08036

Barcelona

DD1 5LA

Dundee

BA11 1EZ

Frome

G45 9AW

Glasgow

L9 7AL

Liverpool

ML1 3JX

Motherwell

HA6 2RN

Northwood

PL6 7TH

Plymouth

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00266253 - A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin | Biotech Hunter | Biotech Hunter